American Banking and Market News logo

The Latest Headlines at American Banking and Market News

Image about Aecon Group Inc. (TSE:ARE) Given Average Recommendation of “Moderate Buy” by Brokerages

Aecon Group Inc. (TSE:ARE) Given Average Recommendation of “Moderate Buy” by Brokerages

Aecon Group Inc. (TSE:ARE – Get Free Report) has received an average rating of “Moderate Buy” from the eleven ratings firms that are presently covering the stock, MarketBeat.com reports. Five research analysts have... More of this article »
Image about Axalta Coating Systems Ltd. (NYSE:AXTA) Receives Consensus Rating of “Hold” from Analysts

Axalta Coating Systems Ltd. (NYSE:AXTA) Receives Consensus Rating of “Hold” from Analysts

Axalta Coating Systems Ltd. (NYSE:AXTA – Get Free Report) has been given an average rating of “Hold” by the thirteen analysts that are currently covering the firm, Marketbeat reports. One investment analyst has... More of this article »
Image about First Solar, Inc. (NASDAQ:FSLR) Given Consensus Rating of “Moderate Buy” by Analysts

First Solar, Inc. (NASDAQ:FSLR) Given Consensus Rating of “Moderate Buy” by Analysts

First Solar, Inc. (NASDAQ:FSLR – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the twenty-one analysts that are covering the company, Marketbeat Ratings reports. Three research... More of this article »
Image about CoStar Group, Inc. (NASDAQ:CSGP) Receives Average Recommendation of “Moderate Buy” from Analysts

CoStar Group, Inc. (NASDAQ:CSGP) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of CoStar Group, Inc. (NASDAQ:CSGP – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the twelve analysts that are covering the firm, Marketbeat.com reports. Two research analysts... More of this article »
Image about TFI International Inc. (NYSE:TFII) Given Average Rating of “Moderate Buy” by Brokerages

TFI International Inc. (NYSE:TFII) Given Average Rating of “Moderate Buy” by Brokerages

Shares of TFI International Inc. (NYSE:TFII – Get Free Report) have received an average recommendation of “Moderate Buy” from the nineteen research firms that are currently covering the firm, MarketBeat Ratings reports.... More of this article »
Image about Veeva Systems Inc. (NYSE:VEEV) Given Average Rating of “Moderate Buy” by Analysts

Veeva Systems Inc. (NYSE:VEEV) Given Average Rating of “Moderate Buy” by Analysts

Shares of Veeva Systems Inc. (NYSE:VEEV – Get Free Report) have received a consensus rating of “Moderate Buy” from the twenty brokerages that are covering the company, Marketbeat.com reports. One research analyst... More of this article »
Image about The Cigna Group (NYSE:CI) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

The Cigna Group (NYSE:CI) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

The Cigna Group (NYSE:CI – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the fourteen analysts that are covering the stock, MarketBeat.com reports. Two research analysts have... More of this article »
Image about 8×8, Inc. (NASDAQ:EGHT) Given Consensus Recommendation of “Moderate Buy” by Brokerages

8×8, Inc. (NASDAQ:EGHT) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of 8×8, Inc. (NASDAQ:EGHT – Get Free Report) have been assigned an average rating of “Moderate Buy” from the six ratings firms that are currently covering the company, MarketBeat reports. Three equities... More of this article »
Image about Oppenheimer Reiterates Outperform Rating for Adobe (NASDAQ:ADBE)

Oppenheimer Reiterates Outperform Rating for Adobe (NASDAQ:ADBE)

Oppenheimer reiterated their outperform rating on shares of Adobe (NASDAQ:ADBE – Free Report) in a research report sent to investors on Friday, Benzinga reports. The brokerage currently has a $660.00 target price on the software... More of this article »
Image about Adobe (NASDAQ:ADBE) Price Target Cut to $700.00

Adobe (NASDAQ:ADBE) Price Target Cut to $700.00

Adobe (NASDAQ:ADBE – Free Report) had its target price reduced by Piper Sandler from $705.00 to $700.00 in a research report sent to investors on Friday morning, Benzinga reports. Piper Sandler currently has an overweight rating... More of this article »
Image about Barclays Trims Adobe (NASDAQ:ADBE) Target Price to $630.00

Barclays Trims Adobe (NASDAQ:ADBE) Target Price to $630.00

Adobe (NASDAQ:ADBE – Free Report) had its price objective lowered by Barclays from $700.00 to $630.00 in a research note released on Friday morning, Benzinga reports. The brokerage currently has an overweight rating on the software... More of this article »
Image about JPMorgan Chase & Co. Trims Adobe (NASDAQ:ADBE) Target Price to $570.00

JPMorgan Chase & Co. Trims Adobe (NASDAQ:ADBE) Target Price to $570.00

Adobe (NASDAQ:ADBE – Free Report) had its price objective reduced by JPMorgan Chase & Co. from $600.00 to $570.00 in a research report sent to investors on Friday, Benzinga reports. They currently have a neutral rating on... More of this article »
Image about Akebia Therapeutics (NASDAQ:AKBA) Receives “Buy” Rating from HC Wainwright

Akebia Therapeutics (NASDAQ:AKBA) Receives “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Akebia Therapeutics (NASDAQ:AKBA – Free Report) in a research note issued to investors on Friday, Benzinga reports. The firm currently has a $5.00 price target on the biopharmaceutical... More of this article »
Image about Align Technology (NASDAQ:ALGN) Given New $350.00 Price Target at Stifel Nicolaus

Align Technology (NASDAQ:ALGN) Given New $350.00 Price Target at Stifel Nicolaus

Align Technology (NASDAQ:ALGN – Free Report) had its target price boosted by Stifel Nicolaus from $340.00 to $350.00 in a report issued on Friday morning, Benzinga reports. They currently have a buy rating on the medical equipment... More of this article »
Image about Allogene Therapeutics (NASDAQ:ALLO) Rating Reiterated by Royal Bank of Canada

Allogene Therapeutics (NASDAQ:ALLO) Rating Reiterated by Royal Bank of Canada

Royal Bank of Canada reiterated their outperform rating on shares of Allogene Therapeutics (NASDAQ:ALLO – Free Report) in a report published on Friday morning, Benzinga reports. They currently have a $10.00 target price on the... More of this article »